异环磷酰胺联合依托泊苷在多线难治性乳腺癌中的疗效及安全分析(1)
 |
| 第1页 |
参见附件(4293KB，5页)。
[摘要] 目的：回顾性评价异环磷酰胺(IFO)与依托泊苷(VP-16)联合方案在多线难治性乳腺癌中的疗效及安全性。方法：化疗方案为IFO 1.5 g/m2，1～5 d静滴3 h；美司钠(Mesna)400 mg，于IFO静滴时1～5 d为0、4、8 h；1～3 d静滴VP-16 100 mg/m2，每4周为1个疗程，化疗周期不超过6个疗程。结果：总共42例患者接受联合方案化疗，客观缓解率(ORR)为26.2%(11/42)，临床获益率为57.1%(24/42)，平均缓解持续时间为5.3个月，无进展时间(TTP)为4.3个月。在10例三阴乳腺癌的亚组中，ORR为40.0%(4/10)，临床获益率为70.0%(7/10)，平均缓解持续时间为5.8个月，TTP为5.0个月。常见的毒副反应是血液学毒性，其中以中性粒细胞减少最常见，没有治疗相关死亡。结论：在多线难治性乳腺癌中，尤其是三阴乳腺癌，异环磷酰胺与依托泊苷联合方案可能是一个有效的化疗方案，毒副反应是可管理的。
[关键词] 异环磷酰胺；依托泊苷；难治性乳腺癌；三阴乳腺癌
[中图分类号] R737.9 [文献标识码] A [文章编号] 1673-7210(2011)07(a)-064-03
Efficacy and safety of the combination of Ifosfamide with Etoposide in heavily pretreated breast cancer
XIAO Jianjun，PENG Jiewen, HE Jinghuan, JIANG Xiaomei, YIN Zhaofeng
Department of Mediacl Oncology, Zhongshan Affilicated Hospital of Sun Yat-sen University, Zhongshan 528403, China.
[Abstract] Objective: To evaluate the efficacy and safety affiliated of the combination of Ifosfamide with Etoposide in heavily pretreated breast cancer retrospectively. Methods: The treatment schedule consisted of ifosfamide 1.5 g/m2 i.v 3 h infusion on day 1-5; mesna 400 mg i.v at 0, 4, 8 h after ifosfamide on day 1-5; and etoposide 100 mg/m2 i.v and given on day 1-3. The treatment cycle was repeated every 4 weeks, and no more than 6 cysles were performed. Result: 42 patients were treated, objective response rate(ORR) was 26.2% (11/42), the clinical benefit was 57.1% (24/42), the median duration of response was 5.3 months, and the median time to disease progression (TTP) was 4.3 months. In the subgroup of 10 patients with triple-negative breast cancer (TNBC), ORR was 40.0% (4/10), the clinical benefit was 70.0% (7/10), the median duration of response was 5.8 months, and TTP was 5.0 months. The most common treatment-related adverse events were hematologic toxicity, especially neutropenia, and no treatment-related death occurred. Conclusion: In heavily pretreated breast cancer, especially TNBC, the combination of Ifosfamide with Etoposide may be a effective regimen, and its adverse events are manageable ......
您现在查看是摘要介绍页，详见PDF附件(4293KB，5页)。